Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism-Importance of slow dissociation and relaxation rates for antiviral efficacy

Biochemical Pharmacology

Volumn 80, Issue 8, 2010, Pages 1133-1140

  Elinder, Malin ^a   Selhorst, Philippe ^b,c   Vanham, Guido ^b,c,d   Öberg, Bo ^e   Vrang, Lotta ^e   Danielson, U Helena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e MEDIVIR AB   (Sweden)

Author keywords

Biosensor; HIV reverse transcriptase; Kinetics; MIV; NNRTI; SPR

Indexed keywords

DAPIVIRINE; DELAVIRDINE; EFAVIRENZ; MIV 170; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; UNCLASSIFIED DRUG; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; BIOSENSOR; DISSOCIATION; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; HUMAN IMMUNODEFICIENCY VIRUS 1; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; WILD TYPE; CELL LINE; CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MONONUCLEAR CELL; STRUCTURE ACTIVITY RELATION;

CELL LINE; DRUG DELIVERY SYSTEMS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 77956225829     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.06.035     Document Type: Article

References (20)

1. Gray R.H., Wawer M.J. Randomised trials of HIV prevention. Lancet 2007, 370:200-201.
2. Cohen J. Retrovirus meeting. Back-to-basics push as HIV prevention struggles. Science 2008, 319:888.
3. Sahlberg C., Zhou X.-X. Development of non-nucleoside reverse transcriptase inhibitors for anti-HIV therapy. Anti-Infective Agents in Medicinal Chemistry 2008, 7:101-117.
4. Nuttall J.P., Thake D.C., Lewis M.G., Ferkany J.W., Romano J.W., Mitchnick M.A. Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days. Antimicrobial Agents and Chemotherapy 2008, 52:909-914.
5. Geitmann M., Unge T., Danielson U.H. Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors. Journal of Medicinal Chemistry 2006, 49:2367-2374.
6. Geitmann M., Unge T., Danielson U.H. Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance. Journal of Medicinal Chemistry 2006, 49:2375-2387.
7. Geitmann M., Danielson U.H. Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis. Bioorganic and Medicinal Chemistry 2007, 15:7344-7354.
8. Geitmann M., Elinder M., de Esch I., Källblad P., Danielson U.H. Fragment screening using SPR biosensors: selection of hits for HIV-1 reverse transcriptase. Fragment Based Lead Discovery Conference 2008.
9. Elinder M., Nordström H., Geitmann M., Hämäläinen M., Vrang L., Öberg B., et al. Screening for NNRTIs with slow dissociation and high affinity for a panel of HIV-1 RT variants. Journal of Biomolecular Screening 2009, 14:395-403.
10. Fletcher P., Harman S., Azijn H., Armanasco N., Manlow P., Perumal D., et al. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrobial Agents and Chemotherapy 2009, 53:487-495.
11. Bhikhabhai R., Carlsson T., Unge T., Lovgren S., Strandberg B. Increased yield of homogeneous HIV-1 reverse transcriptase (p66/p51) using a slow purification approach. Journal of Chromatography 1993, 639:67-74.
12. Högberg M., Sahlberg C., Engelhardt P., Noreen R., Kangasmetsä J., Johansson N.G., et al. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors 3. Synthesis and further structure-activity relationship studies of PETT analogues. Journal of Medicinal Chemistry 1999, 42:4150-4160.
13. Beirnaert E., Willems B., Peeters M., Bouckaert A., Heyndrickx L., Zhong P., et al. Design and evaluation of an in-house HIV-1 (group M and O) SIVmnd and SIVcpz antigen capture assay. Journal of Virological Methods 1998, 73:65-70.
14. Spence R.A., Kati W.M., Anderson K.S., Johnson K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995, 267:988-993.
15. Önell A., Andersson K. Kinetic determinations of molecular interactions using Biacore-minimum data requirements for efficient experimental design. Journal of Molecular Recognition 2005, 18:307-317.
16. Gupta J., Sharma P., Romano J., Garg S. Application of nanotechnology to enhance the solubility of poorly water soluble drug dapivirine. ISPE Australasia Conference 2009.
17. Motakis D., Parniak M.A. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotheraphy 2002, 46:1851-1856.
18. Williams J.W., Morrison J.F. The kinetics of reversible tight-binding inhibition. Methods Enzymology 1979, 63:437-467.
19. Weikl T.R., von Deuster C. Selected-fit versus induced-fit protein binding: kinetic differences and mutational analysis. Proteins 2009, 75:104-110.
20. Shuman C.F., Vrang L., Danielson U.H. Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data. Journal of Medicinal Chemistry 2004, 47:5953-5961.